Many established medical therapies to treat myasthenia gravis remain in use, and newer options are available for patients who ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

The myasthenia gravis (MG) market across the seven major markets (7MM: France, Germany, Italy, Japan, Spain, the UK and the ...

UCB, a global biopharmaceutical company, today announced that 15 scholarships were awarded to people impacted by myasthenia gravis in the U.S. The UCB Myasthenia Gravis Scholarship™ exemplifies UCB's ...

Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...

Mark Horton, an archaeology professor at the Royal Agricultural University in the United Kingdom, spoke with Fox News Digital ...

Its growth is attributed to the anticipated launch of seven late-stage pipeline therapies. The myasthenia gravis (MG) market ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Rare disease community members take action in June to spread awareness and advocate for better treatments and a cure for myasthenia gravis Global MG Community turns Awareness into Action to ...